Diabetes Caused by Statin Use: A Review

Risa Zulfiana, Farah Medina, Suharjono Suharjono

Abstract


Statins are generally recognised as being safe and well tolerated cholesterol-lowering drug and have been successfully used for prevention of primary and secondary cardiovascular disease. However, Some researchers have reported diabetes development in patients taking statins. A number of meta-analyses conducted in recent years have proved that the association is real even though its causality have not been fully elucidated. Various pathophysiological mechanisms that could explain the increased risk of diabetes in patients treated with statin have been described. These are mainly responsible for impairment of β -cell insulin secretion and alteration of intercellular signaling through depletion of important downstream products.  This review aims to examine the relationship between statin treatment and the presence of diabetes. Previous clinical reviews of the evidence and pathophysiological mechanisms involved may also be explained. Furthermore, many studies have concluded that Pitavastatin and pravastatinom do not affect glycemic control and may be a beneficial treatment option in patients with, or at risk for, type 2 diabetes.


Full Text:

PDF

References


Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, Moran AE. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Archives of medical research. 2015 Jul 1;46(5):328-38.

Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circulation research. 2017 Jan 6;120(1):229-43.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Jun 17;73(24):e285-350.

Davies JT, Delfino SF, Feinberg CE, Johnson MF, Nappi VL, Olinger JT, Schwab AP, Swanson HI. Current and emerging uses of statins in clinical therapeutics: a review. Lipid insights. 2016 Jan;9:LPI-S37450.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology. 2019 Feb;39(2):e38-81.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 2010 Feb 27;375(9716):735-42.

Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta‐analysis. Pharmacoepidemiology and drug safety. 2016 Oct;25(10):1131-49.

Engeda JC, Stackhouse A, White M, Rosamond WD, Lhachimi SK, Lund JL, Keyserling TC, Avery CL. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. Diabetes research and clinical practice. 2019 May 1;151:96-105.

Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. Journal of pharmacology & pharmacotherapeutics. 2014 Jul;5(3):181.

Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes care. 2009 Oct 1;32(10):1924-9.

Rochlani Y, Kattoor AJ, Pothineni NV, Palagiri RD, Romeo F, Mehta JL. Balancing primary prevention and statin-induced diabetes mellitus prevention. The American journal of cardiology. 2017 Oct 1;120(7):1122-8.

Stančáková A, Kuulasmaa T, Paananen J, Jackson AU, Bonnycastle LL, Collins FS, Boehnke M, Kuusisto J, Laakso M. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes. 2009 Sep 1;58(9):2129-36.

Salunkhe VA, Elvstam O, Eliasson L, Wendt A. Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1 832/13 cells. PLoS One. 2016 Mar 17;11(3):e0151592.

Shigematsu S, Khan AH, Kanzaki M, Pessin JE. Intracellular insulin-responsive glucose transporter (GLUT4) distribution but not insulin-stimulated GLUT4 exocytosis and recycling are microtubule dependent. Molecular endocrinology. 2002 May 1;16(5):1060-8.

Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms?. Current opinion in lipidology. 2015 Jun 1;26(3):228-35.

Dugani SB, Akinkuolie AO, Paynter N, Glynn RJ, Ridker PM, Mora S. Association of lipoproteins, insulin resistance, and rosuvastatin with incident type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA cardiology. 2016 May 1;1(2):136-45.

Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes. FEBS letters. 2001 Nov 2;507(3):357-61.

Ciosek CP, Magnin DR, Harrity TW, Logan JV, Dickson JK, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM. Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. Journal of Biological Chemistry. 1993 Nov 25;268(33):24832-7.

Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences. 1990 Nov 1;87(22):8931-4.

Odawara, M. & Yamazaki, T. & Kishimoto, J. & Ito, C. & Noda, Mitsuhiko & Terauchi, Yasuo & Shiba, T. & Kitazato, H. & Maemura, K. & Tobe, K. & Iwamoto, Yasuhiko & Akanuma, Y. & Kadowaki, T. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. 2013; S59-S59.

Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Current opinion in lipidology. 2015 Jun 1;26(3):228-35.

Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014 Jun 1;63(6):735-45.




DOI: https://doi.org/10.18860/jip.v5i1.8652

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Risa Zulfiana, Farah Medina, Suharjono Suharjono



© 2023 Journal of Islamic Pharmacy